Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Condition: Myelofibrosis · Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Sponsor: Novartis Pharmaceuticals
About this study
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (156)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers | Chandler, Arizona, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL | Decatur, Illinois, United States | — |
| Franciscan Health/Indiana blood and Marrow Transplantation | Indianapolis, Indiana, United States | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville, Kentucky, United States | — |
| University of Michigan Medical Center | Ann Arbor, Michigan, United States | — |
+ 144 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04603495